Akari Therapeutics shares jumped on Wednesday after the firm announced that the FDA has granted Fast Track designation for its stem cell transplant treatment.
Chris Lange
Shares of Akari Therapeutics saw a handy gain on Friday after the firm announced that the FDA granted a Fast Track designation for its treatment of paroxysmal nocturnal hemoglobinuria.
Chris Lange
24/7 Wall St. has collected a few pharma and biotech catalysts that are coming up on the calendar in November and December.
Chris Lange
Akari Therapeutics has announced preliminary results from the first paroxysmal nocturnal hemoglobinuria patient treated with subcutaneously administered Coversin.
Chris Lange
The top analyst upgrades, downgrades and other research calls on Friday include Ambac, Bed Bath & Beyond, General Electric, Tiffany and Trade Desk.
Jon C. Ogg